Pharmaceutical Crystals

Uekusa, Hidehiro; Yonemochi, Etsuo

doi:10.3390/books978-3-03928-713-0

dc.contributor.author	Uekusa, Hidehiro	*
dc.contributor.author	Yonemochi, Etsuo	*
dc.date.accessioned	2021-02-11T22:44:34Z
dc.date.available	2021-02-11T22:44:34Z
dc.date.issued	2020	*
dc.date.submitted	2020-06-09 16:38:57	*
dc.identifier	45988	*
dc.identifier.uri	https://directory.doabooks.org/handle/20.500.12854/56130
dc.description.abstract	The crystalline state is the most commonly used essential solid active pharmaceutical ingredient (API). The characterization of pharmaceutical crystals encompasses many scientific disciplines, but the core is crystal structure analysis, which reveals the molecular structure of essential pharmaceutical compounds. Crystal structure analysis provides important structural information related to the API's wide range of physicochemical properties, such as solubility, stability, tablet performance, color, and hygroscopicity. This book entitled “Pharmaceutical Crystals"" focuses on the relationship between crystal structure and physicochemical properties. In particular, the new crystal structure of pharmaceutical compounds involving multi-component crystals, such as co-crystals, salts, and hydrates, and polymorph crystals are reported. Such crystal structures were investigated in the latest studies that combined morphology, spectroscopic, theoretical calculation, and thermal analysis with crystallographic study. This book highlights the importance of crystal structure information in many areas of pharmaceutical science and presents current trends in the structure–property study of pharmaceutical crystals. The Guest Editors of this book hope the readers enjoy a wide variety of recent studies on Pharmaceutical Crystals.	*
dc.language	English	*
dc.subject	QD1-999	*
dc.subject	Q1-390	*
dc.subject	QD450-801	*
dc.subject.classification	thema EDItEUR::P Mathematics and Science::PN Chemistry	en_US
dc.subject.other	crystal structure analysis	*
dc.subject.other	n/a	*
dc.subject.other	famotidine	*
dc.subject.other	solution crystallization	*
dc.subject.other	salt optimization	*
dc.subject.other	structure determination from powder diffraction data	*
dc.subject.other	Hirshfeld surface analysis	*
dc.subject.other	DFT	*
dc.subject.other	molecular docking study	*
dc.subject.other	melting diagram	*
dc.subject.other	dehydration	*
dc.subject.other	hygroscopicity	*
dc.subject.other	HBV	*
dc.subject.other	Benzodioxole	*
dc.subject.other	pharmaceutical crystals	*
dc.subject.other	4-b]indol-4-one	*
dc.subject.other	pyrimidin-4(3H)-one	*
dc.subject.other	liquid assisted grinding	*
dc.subject.other	HOMO-LUMO	*
dc.subject.other	dissolution	*
dc.subject.other	cocrystal formation	*
dc.subject.other	Raman spectroscopy	*
dc.subject.other	carbamazepine	*
dc.subject.other	hydrogen bonding	*
dc.subject.other	3	*
dc.subject.other	ondansetron	*
dc.subject.other	physicochemical properties	*
dc.subject.other	solubility	*
dc.subject.other	succinic acid	*
dc.subject.other	cocrystal	*
dc.subject.other	adefovir dipivoxil	*
dc.subject.other	hepatitis B	*
dc.subject.other	polymorphs	*
dc.subject.other	hydrogen-bond-acceptance ability	*
dc.subject.other	DFT study	*
dc.subject.other	Nitrofurantoin–4-dimethylaminopyridine (NF-DMAP) salt	*
dc.subject.other	photostability	*
dc.subject.other	on-line monitoring	*
dc.subject.other	5-dihydro-4H-pyrimido[5	*
dc.subject.other	Imidazole	*
dc.subject.other	Semicarbazone	*
dc.subject.other	crystal habit	*
dc.subject.other	Crystal structure	*
dc.subject.other	solvent-mediated polymorphic transformation	*
dc.subject.other	ticagrelor	*
dc.subject.other	hydrate	*
dc.subject.other	pharmaceutical cocrystal	*
dc.subject.other	malonic acid	*
dc.subject.other	1H-indole	*
dc.subject.other	reactivity descriptors	*
dc.subject.other	famoxadone	*
dc.subject.other	crystal structure	*
dc.subject.other	dicarboxylic acid	*
dc.subject.other	hydrogen bond	*
dc.subject.other	saccharin	*
dc.title	Pharmaceutical Crystals	*
dc.type	book
oapen.identifier.doi	10.3390/books978-3-03928-713-0	*
oapen.relation.isPublishedBy	46cabcaa-dd94-4bfe-87b4-55023c1b36d0	*
oapen.relation.isbn	9783039287123	*
oapen.relation.isbn	9783039287130	*
oapen.pages	148	*
oapen.edition	1st	*

Fichier(s) constituant ce document

Fichiers	Taille	Format	Vue
Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Imported or submitted locally

Afficher la notice abrégée

Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by-nc-nd/4.0/